“I have no medical or statistical training to kn
Post# of 148300
IMO, the number of COVId infected patients among the current HIV population on leronlimab is irrelevant. Why? The sample is small. HIV patients are likely to protect themselves more from COVID19 (Lowe infection rate), and COVId infection isn’t part of the study. Additionally, CYDY can not afford another trial to look at COVID19 prevention for cost reasons and it would never be a very smart economic choice as you’d need multiple doses.